Skip to content

Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation

Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00289653
Enrollment
23
Registered
2006-02-10
Start date
2005-09-30
Completion date
2009-07-31
Last updated
2018-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence

Keywords

nicotine dependence,, transdermal nicotine patch,, smoking while receiving nicotine replacement,, comorbidities

Brief summary

Smoking while on nicotine patches will help subjects to reduce their expired carbon monoxide levels from the levels they were before they started using the patch. Subjects will also decrease their daily consumption of cigarettes.

Detailed description

Subjects who smoke while on an individually dosed tNRT will reduce their expired carbon monoxide levels from pre- to post-treatment conditions. They will also decrease their daily consumption of cigarettes.

Interventions

Sponsors

Centre for Addiction and Mental Health
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* at least 19 years of age * male or female * have intention to quit smoking within the next 6 months * smoke 10 or more cigarettes per day

Exclusion criteria

* Pregnant or not using an adequate enough method of birth control to ensure that they are not at risk of becoming pregnant * breastfeeding * have any generalized skin disorders * are in an immediate post-myocardial infarction period or have life-threatening arrhythmias, have severe or worsening angina pectoris or have had a recent cerebral vascular accident * are using additional nicotine replacement therapies or any other smoking cessation pharmacotherapy * any clinically significant ECG abnormalities * any known hypersensitivity to components of the transdermal system

Design outcomes

Primary

MeasureTime frameDescription
Carbon Monoxide Levelsmeasured at week 10Expired Co levels were measured to confirm smoking status

Secondary

MeasureTime frameDescription
Smoking CessationWeek 10self reported # cigarettes per day

Countries

Canada

Participant flow

Participants by arm

ArmCount
Enrolled Participants
All eligible enrolled participants
23
Total23

Baseline characteristics

CharacteristicEnrolled Participants
Age, Continuous45.4 years
STANDARD_DEVIATION 12.4
Beck Depression Inventory (BDI) score10.0 units on a scale
STANDARD_DEVIATION 9.7
Carbon monoxide gas (CO) reading23.1 ppm
STANDARD_DEVIATION 11.5
Fagerstrom Test of Nicotine Dependence6.3 units on a scale
STANDARD_DEVIATION 2.3
Hamilton Depression Rating Scale (HAM-D)8.9 units on a scale
STANDARD_DEVIATION 9.8
Mean Cigarettes per day25.7 cigarettes per day
STANDARD_DEVIATION 13.4
No. of previous serious quit attempts4.7 Quit attempts
STANDARD_DEVIATION 6.3
No. years smoking30.1 years
STANDARD_DEVIATION 12.9
Sex: Female, Male
Female
11 Participants
Sex: Female, Male
Male
12 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 23
other
Total, other adverse events
17 / 23
serious
Total, serious adverse events
0 / 23

Outcome results

Primary

Carbon Monoxide Levels

Expired Co levels were measured to confirm smoking status

Time frame: measured at week 10

ArmMeasureValue (MEAN)Dispersion
Enrolled ParticipantsCarbon Monoxide Levels9.2 parts per millionStandard Deviation 6.3
Secondary

Smoking Cessation

self reported # cigarettes per day

Time frame: Week 10

ArmMeasureValue (MEAN)Dispersion
Enrolled ParticipantsSmoking Cessation3.7 cigarettes per dayStandard Deviation 4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026